William Blair Has Bearish Forecast for AUTL FY2024 Earnings

Autolus Therapeutics plc (NASDAQ:AUTL) – Research analysts at William Blair cut their FY2024 earnings per share (EPS) estimates for Autolus Therapeutics in a report released on Tuesday, November 12th. William Blair analyst M. Phipps now expects that the company will post earnings of ($1.09) per share for the year, down from their prior estimate of ($0.92). The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.84) per share. William Blair also issued estimates for Autolus Therapeutics’ Q4 2024 earnings at ($0.33) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.53) EPS.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the firm posted ($0.26) EPS.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, November 11th. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Autolus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $9.45.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $3.08 on Friday. The firm’s 50-day moving average is $3.91 and its two-hundred day moving average is $3.98. Autolus Therapeutics has a 12-month low of $2.94 and a 12-month high of $7.45. The company has a market capitalization of $819.56 million, a PE ratio of -2.55 and a beta of 2.04.

Institutional Trading of Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in shares of Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the period. State Street Corp grew its position in Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares in the last quarter. HighVista Strategies LLC raised its stake in shares of Autolus Therapeutics by 2.7% during the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after purchasing an additional 14,204 shares during the period. Erste Asset Management GmbH purchased a new position in shares of Autolus Therapeutics in the third quarter valued at $708,000. Finally, Bellevue Group AG grew its holdings in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.